US2005255138A1PendingUtilityA1

Active agent transport systems

Assignee: MILSTEIN SAM JPriority: Jun 15, 1992Filed: Jan 24, 2005Published: Nov 17, 2005
Est. expiryJun 15, 2012(expired)· nominal 20-yr term from priority
A61K 9/1641C07C 233/55C07C 229/42C07C 2601/02A61K 31/16A61K 8/0241A61K 9/2013A61K 38/25A61K 31/715A61K 8/64C07C 235/64A61K 31/35C07C 2601/18C07K 5/06043A61K 38/28A61K 9/1617C07C 237/22C07C 233/87A61K 31/28A61K 31/727A61K 38/27C07C 2601/14C07C 235/84C07K 1/1077A61K 38/212A61Q 13/00C07C 235/38C07C 279/14C07C 2601/08C07C 233/63A61K 2800/56A61K 38/23A61K 9/167A61K 47/62A61K 31/352A61K 47/12A61K 47/18
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for transporting a biologically active agent across a cellular membrane or a lipid bilayer. A first method includes the steps of: (a) providing a biologically active agent which can exist in a native conformational state, a denatured conformational state, and an intermediate conformational state which is reversible to the native state and which is conformationally between the native and denatured states; (b) exposing the biologically active agent to a complexing perturbant to reversibly transform the biologically active agent to the intermediate state and to form a transportable supramolecular complex; and (c) exposing the membrane or bilayer to the supramolecular complex, to transport the biologically active agent across the membrane or bilayer. The perturbant has a molecular weight between about 150 and about 600 daltons, and contains at least one hydrophilic moiety and at least one hydrophobic moiety. The supramolecular complex comprises the perturbant non-covalently bound or complexed with the biologically active agent. In the present Invention, the biologically active agent does not form a microsphere after interacting with the perturbant. A method for preparing an orally administrable biologically active agent comprising steps (a) and (b) above is also provided as are oral delivery compositions. Additionally, mimetics and methods for preparing mimetics are contemplated.

Claims

exact text as granted — not AI-modified
1 - 22 . (canceled)  
   
   
       23 . An oral delivery composition comprising a peptide mimetic of a peptidic biologically active agent having a native state, a denatured state, and an intermediate state conformationally between said native and denatured states, wherein said intermediate state is reversible to said native state.

Join the waitlist — get patent alerts

Track US2005255138A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.